FDA indications According to the Prescribing Information, the wording of the FDA indications for semaglutide injection (Wegovy ) is as follows (the emphasis below in red has been added by us): WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
Perrone, S., Negro, S., Tataranno, M
GLP-1 medications prescribed to treat type 2 diabetes may affect a persons sense of smell and taste, according to a new study
But the evidence is not crystal clear about the prevention of those serious complications, says Michael Hochman, MD, MPH, director of the Gehr Family Center for Health Systems Science and Innovation at the Keck School of Medicine of USC in Los Angeles